Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 3,038,967 shares, a growth of 1,004.7% from the April 15th total of 275,084 shares. Based on an average trading volume of 17,378,163 shares, the short-interest ratio is presently 0.2 days. Approximately 29.1% of the shares of the stock are sold short.

Institutional Trading of Calidi Biotherapeutics

Hedge funds have recently modified their holdings of the business. Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the third quarter valued at $28,000. Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the fourth quarter valued at $25,000. Geode Capital Management LLC lifted its holdings in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC purchased a new stake in shares of Calidi Biotherapeutics in the fourth quarter valued at $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Stock Up 8.1%

Shares of CLDI traded up $0.02 during mid-day trading on Wednesday, reaching $0.20. The company’s stock had a trading volume of 2,154,541 shares, compared to its average volume of 10,658,096. The business has a fifty day moving average of $0.29 and a 200 day moving average of $0.88. The company has a market cap of $2.18 million, a price-to-earnings ratio of -0.03 and a beta of 1.38. Calidi Biotherapeutics has a 1 year low of $0.18 and a 1 year high of $19.20. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.21.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its earnings results on Friday, March 27th. The company reported $0.45 earnings per share (EPS) for the quarter.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.